Pfizer Targets Post-2028 Growth with Obesity and Cancer Drugs

Pfizer plans to regain growth momentum from 2028 onward, supported by its newly developed obesity and cancer drugs. The company expects sales to increase significantly as it begins to reap the benefits of its R&D efforts in these areas. In particular, candidate drugs for obesity treatment are anticipated to appeal to a broad patient population. Pfizer's management states that despite patent expirations and declining sales of some products in its current portfolio, new drugs will fill this gap. Innovative cancer treatments are also said to play a key role in the company's growth strategy. Accordingly, the company targets a marked improvement in both revenue and profitability in the post-2028 period. While aware of intense competition in the obesity drug market, the company hopes to gain an advantage through differentiated mechanisms of action and side effect profiles. In the cancer field, advances in immunotherapy and targeted therapies support Pfizer's growth expectations. These strategic moves aim to enhance the company's long-term value creation potential. This is not investment advice.